Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib

Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging

(2017) Seunghyun Lee et al.   EUROPEAN RADIOLOGY

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

(2017) Caroline Randrup Hansen et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them

(2017) Jordi Bruix et al.   JOURNAL OF HEPATOLOGY

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

(2017) Riccardo Lencioni et al.   JOURNAL OF HEPATOLOGY

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1

(2016) M. Gavanier et al.   EUROPEAN JOURNAL OF RADIOLOGY

Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma?

(2016) Matteo Renzulli et al.   RADIOLOGY

Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma

(2015) Adeel R. Seyal et al.   HEPATOLOGY

Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)

(2015) Masatoshi Kudo et al.   HEPATOLOGY RESEARCH

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma

(2014) Tadaaki Arizumi et al.   JOURNAL OF GASTROENTEROLOGY

Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

(2014) M. Ronot et al.   ONCOLOGIST

Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?

(2014) Irene Bargellini et al.   ONCOLOGY

Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer

(2012) Madhavi Nagilla et al.   ADVANCES IN THERAPY

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602

(2012) Yozo Sato et al.   UPSALA JOURNAL OF MEDICAL SCIENCES

Extrahepatic Spread of Hepatocellular Carcinoma: Spectrum of Imaging Findings

(2011) Darryl B. Sneag et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians

(2011) Yongsheng Wang et al.   Therapeutic Advances in Medical Oncology

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE